Reirradiation in recurrent glioblastoma

J 2025

Reirradiation in recurrent glioblastoma

KAZDA, Tomáš; Lucie HNIDÁKOVÁ a Giuseppe MINNITI

Základní údaje

Originální název

Reirradiation in recurrent glioblastoma

Autoři

KAZDA, Tomáš; Lucie HNIDÁKOVÁ a Giuseppe MINNITI

Vydání

Current Opinion in Oncology, Philadelphia, Lippincott Williams and Wilkins, 2025, 1040-8746

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.400 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00143825

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

glioblastoma; high-grade gliomas; LEGATO trial; reirradiation

Štítky

14110812, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 3. 2026 11:43, Mgr. Tereza Miškechová

Anotace

V originále

Purpose of reviewReirradiation has emerged as a potentially valuable treatment strategy for recurrent glioblastoma, a disease characterized by inevitable local progression despite aggressive multimodal first-line therapy. Recent advances in radiotherapy techniques, improved patient selection, and evolving systemic treatment combinations have renewed clinical interest in this approach. This is reflected by recent publication of the first international consensus guidelines (ESTRO/EANO) and the initiation of an European phase III randomized trial on reirradiation of patients with recurrent glioblastoma.Recent findingsRetrospective and early-phase prospective studies have demonstrated that reirradiation is feasible and well tolerated in selected patients, with median overall survival ranging from 7 to 13 months. The ESTRO/EANO guidelines on reirradiation of glioma provide standardized recommendations for patient selection, dose constraints, and target volume delineation. Meta-analyses suggest improved outcomes when reirradiation is combined with systemic therapies, such as bevacizumab or lomustine. The phase III EORTC-2227-BTG (LEGATO) trial will provide definitive data on survival benefit.SummaryReirradiation is gaining acceptance as a palliative yet potentially impactful treatment for recurrent glioblastoma. While current evidence supports its use in selected cases, results from ongoing phase III LEGATO trial will determine its future role in standard care and inform evidence-based clinical decision-making.

Citovat

KAZDA, Tomáš; Lucie HNIDÁKOVÁ a Giuseppe MINNITI. Reirradiation in recurrent glioblastoma. Current Opinion in Oncology. Philadelphia: Lippincott Williams and Wilkins, 2025, roč. 37, č. 6, s. 580-588. ISSN 1040-8746. Dostupné z: https://doi.org/10.1097/CCO.0000000000001192.

@article{2557774,
   author = {Kazda, Tomáš and Hnidáková, Lucie and Minniti, Giuseppe},
   article_location = {Philadelphia},
   article_number = {6},
   doi = {https://doi.org/10.1097/CCO.0000000000001192},
   keywords = {glioblastoma; high-grade gliomas; LEGATO trial; reirradiation},
   language = {eng},
   issn = {1040-8746},
   journal = {Current Opinion in Oncology},
   title = {Reirradiation in recurrent glioblastoma},
   url = {https://journals.lww.com/co-oncology/fulltext/2025/11000/reirradiation_in_recurrent_glioblastoma.8.aspx},
   volume = {37},
   year = {2025}
}

TY  - JOUR
ID  - 2557774
AU  - Kazda, Tomáš - Hnidáková, Lucie - Minniti, Giuseppe
PY  - 2025
TI  - Reirradiation in recurrent glioblastoma
JF  - Current Opinion in Oncology
VL  - 37
IS  - 6
SP  - 580-588
EP  - 580-588
PB  - Lippincott Williams and Wilkins
SN  - 10408746
KW  - glioblastoma
KW  - high-grade gliomas
KW  - LEGATO trial
KW  - reirradiation
UR  - https://journals.lww.com/co-oncology/fulltext/2025/11000/reirradiation_in_recurrent_glioblastoma.8.aspx
N2  - Purpose of reviewReirradiation has emerged as a potentially valuable treatment strategy for recurrent glioblastoma, a disease characterized by inevitable local progression despite aggressive multimodal first-line therapy. Recent advances in radiotherapy techniques, improved patient selection, and evolving systemic treatment combinations have renewed clinical interest in this approach. This is reflected by recent publication of the first international consensus guidelines (ESTRO/EANO) and the initiation of an European phase III randomized trial on reirradiation of patients with recurrent glioblastoma.Recent findingsRetrospective and early-phase prospective studies have demonstrated that reirradiation is feasible and well tolerated in selected patients, with median overall survival ranging from 7 to 13 months. The ESTRO/EANO guidelines on reirradiation of glioma provide standardized recommendations for patient selection, dose constraints, and target volume delineation. Meta-analyses suggest improved outcomes when reirradiation is combined with systemic therapies, such as bevacizumab or lomustine. The phase III EORTC-2227-BTG (LEGATO) trial will provide definitive data on survival benefit.SummaryReirradiation is gaining acceptance as a palliative yet potentially impactful treatment for recurrent glioblastoma. While current evidence supports its use in selected cases, results from ongoing phase III LEGATO trial will determine its future role in standard care and inform evidence-based clinical decision-making.
ER  -

KAZDA, Tomáš; Lucie HNIDÁKOVÁ a Giuseppe MINNITI. Reirradiation in recurrent glioblastoma. \textit{Current Opinion in Oncology}. Philadelphia: Lippincott Williams and Wilkins, 2025, roč.~37, č.~6, s.~580-588. ISSN~1040-8746. Dostupné z: https://doi.org/10.1097/CCO.0000000000001192.

Přehled o publikaci